Global Bio-chem Technology Group (HKG:0809) expects a net gain (excluding tax effect) of between HK$600 million and HK$800 million for the year 2024, down from HK$4.18 billion a year prior, a Thursday filing with the Hong Kong bourse said.
The biotech firm attributed the lower anticipated net gain mainly to the absence of a one-off gain of roughly HK$4.28 billion on completion of a debt restructuring agreement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.